BCR and myeloid neoplasm: Evidence for BCL2 inhibition in this setting is limited to anecdotal reports, including a recent case describing prolonged disease control with ruxolitinib plus venetoclax in a BCR::JAK2-rearranged myeloid neoplasm, suggesting potential synergistic activity of JAK2 and BCL2 blockade [32].